Investigational Drug Information for ABBV-951
✉ Email this page to a colleague
What is the development status for investigational drug ABBV-951?
ABBV-951 is an investigational drug.
There have been 7 clinical trials for ABBV-951.
The most recent clinical trial was a Phase 3 trial, which was initiated on June 8th 2020.
The most common disease conditions in clinical trials are Parkinson Disease and [disabled in preview]. The leading clinical trial sponsors are AbbVie and [disabled in preview].
There is one US patent protecting this investigational drug and two hundred and eighty-six international patents.
Summary for ABBV-951
| US Patents | 1 |
| International Patents | 286 |
| US Patent Applications | 54 |
| WIPO Patent Applications | 73 |
| Japanese Patent Applications | 47 |
| Clinical Trial Progress | Phase 3 (2020-06-08) |
| Vendors | 15 |
Recent Clinical Trials for ABBV-951
| Title | Sponsor | Phase |
|---|---|---|
| Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson's Disease | AbbVie | Phase 1 |
| Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease | AbbVie | Phase 3 |
| Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease | AbbVie | Phase 3 |
Clinical Trial Summary for ABBV-951
Top disease conditions for ABBV-951
Top clinical trial sponsors for ABBV-951
US Patents for ABBV-951
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| ABBV-951 | ⤷ Subscribe | Topical with static photobiological functionality | Maple Ridge Group, LLC (New York, NY) | ⤷ Subscribe |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for ABBV-951
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| ABBV-951 | Argentina | AR102389 | 2034-10-21 | ⤷ Subscribe |
| ABBV-951 | Australia | AU2015335941 | 2034-10-21 | ⤷ Subscribe |
| ABBV-951 | Australia | AU2021201414 | 2034-10-21 | ⤷ Subscribe |
| ABBV-951 | Brazil | BR112017008198 | 2034-10-21 | ⤷ Subscribe |
| ABBV-951 | Canada | CA2965379 | 2034-10-21 | ⤷ Subscribe |
| ABBV-951 | China | CN107206013 | 2034-10-21 | ⤷ Subscribe |
| ABBV-951 | China | CN111362980 | 2034-10-21 | ⤷ Subscribe |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
